Three-dimensional quantitative structure activity relationship analysis of anilinoquinazolines for c-Src kinase inhibition

Medicinal Chemistry Research

Volumn 20, Issue 2, 2011, Pages 158-167

  Silakari, Pratigya ^a   Srivastava, Savitri Devi ^a   Kohli, Dharam Veer ^a   Srivastava, Santosh Kumar ^a   Silakari, Gyati ^a   Vyas, Bhawna ^b   Silakari, Om ^c  

^a DR H S GOUR UNIVERSITY   (India)

^b Multani Mal Modi College   (India)

^c PUNJABI UNIVERSITY   (India)

Author keywords

Anilinoquinazolines; c Src kinase; Molecular Fields Analysis; QSAR

Indexed keywords

ANILINOQUINAZOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; C SRC KINASE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ENZYME INHIBITION; IC 50; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 79952709182     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-010-9301-x     Document Type: Article

References (26)

1. Abram CL, Courtneidge SA (2000) Src family tyrosine kinases and growth factor signaling. Exp Cell Res 254:1-13 (Pubitemid 30066726)
2. Bjorge JD, Jakymiw A, Fujita DJ (2000) Selected glimpses into the activation and function of Src kinase. Oncogene 19:5620-5635
3. Brown MT, Cooper JA (1996) Regulation, substrates and functions of src. Biochim Biophys Acta 1287:121-149 (Pubitemid 26189191)
4. Cao R, Mi N, Zhang H (2009) 3D-QSAR study of c-Src kinase inhibitors based on docking. J Mol Model. doi:10.1007/s00894-009-0530-1
5. Cerius2 Molecular Modeling Program Package, Molecular Simulations (Accelrys) Inc., San Diego, CA 92121-3752, USA
6. Dewar MJS, Zoebisch EG, Healy EF, Stewart JP (1985) AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107:3902-3909
7. Fan Y, Shi LM, Kohn KW, Pommier Y, Weinstein JN (2001) Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. J Med Chem 44:3254-3263 (Pubitemid 32917105)
8. Frame MC, Fincham VJ, Carragher NO, Wyke JA (2002) v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 3:233-245 (Pubitemid 34619259)
9. Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36:3219-3228
10. 2. J Mol Graph Model 20:269-276
11. Hansch C, Kurup A, Garg R, Gao H (2001) Chem-bioinformatics and QSAR: a review of QSAR lacking positive hydrophobic terms. Chem Rev 101:619-672 (Pubitemid 35377680)
12. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Ple' PA, Warin N, Costello G (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4- methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available dual-specific c-Src/Abl kinase inhibitor. J Med Chem 49:6465-6488 (Pubitemid 44657442)
13. Hopfinger AJ, Tokarsi JS, Charifson PS (1997) Practical applications of computer-aided drug design. Marcel Dekker, New York
14. Hunter T (1998) The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect 94:81-119
15. Martin GS (2001) The hunting of the Src. Nat Rev Mol Cell Biol 2:467-475
16. Mayo SL, Olafson BD, Goddard WA (1990) DREIDING: a generic force field for molecular simulations. J Phys Chem 94:8897-8909
17. Neet K, Hunter T (1996) Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1:147-169 (Pubitemid 126673114)
18. Oprea TI, Waller CL, Marshall GR (1994) Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. J Med Chem 37:2206-2215
19. Plé PA, Green TP, Hennequin LF, Curwen J, Fennell M, Allen J, Lambert-Van Der Brempt C, Costello G (2004) Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 47:871-887 (Pubitemid 38176790)
20. Russello SV, Shore SK (2004) SRC in human carcinogenesis. Fron Biosci 9:139-144 (Pubitemid 38925447)
21. Thaimattam R, Daga PR, Banerjee R, Iqbal J (2005) 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg Med Chem 13:4704-4712 (Pubitemid 40848348)
22. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513-609 (Pubitemid 28034534)
23. Tsygankov AY, Shore SK (2004) Src: regulation, role in human carcinogenesis and pharmacological inhibitors. Curr Pharm Des 15:1745-1756 (Pubitemid 38647457)
24. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212
25. van der Geer P, Hunter T, Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10:251-337 (Pubitemid 24372822)
26. Wold S, van de Waterbeemd H (1995) Chemometric methods in molecular design. VCH, Weinheim